The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group
Open accessAbstract
Purpose: Chemotherapy with alternating vincristine-doxorubicin-cyclophosphamide and ifosfamide-etoposide cycles and primary tumor treatment with surgery and/or radiation therapy constitute the usual approach to localized Ewing sarcoma in North America. We tested whether chemotherapy intensification through interval compression could improve outcome. Patients and Methods: This was a prospective, randomized controlled trial for patients younger than 50 years old with newly diagnosed localized extradural Ewing sarcoma. Patients assigned to standard and intensified treatment were to begin chemotherapy cycles every 21 and 14 days, respectively, provided an absolute neutrophil count greater than 750 × 10 6 /L and a platelet count greater than 75 × 10 9 /L. Patients received vincristine (2 mg/m 2 ), doxorubicin (75 mg/m 2 ), and cyclophosphamide (1.2 g/m 2 ) alternating with ifosfamide (9 g/m 2 ) and etoposide (500 mg/m 2 ) for 14 cycles, with filgrastim (5 mg/kg per day; maximum, 300 mg) between cycles. Primary tumor treatment (surgery, radiation, or both) was to begin at week 13 (after four cycles in the standard arm and six cycles in the intensified arm). The primary end point was event-free survival (EFS). The study is registered at ClinicalTrials.gov (identifier: NCT00006734). Results: Five hundred eighty-seven patients were enrolled and randomly assigned, and 568 patients were eligible, with 284 patients in each regimen. For all cycles, the median cycle interval for standard treatment was 21 days (mean, 22.45 days); for intensified treatment, the median interval was 15 days (mean, 17.29 days). EFS at a median of 5 years was 65% in the standard arm and 73% in the intensified arm (P = .048). The toxicity of the regimens was similar. Conclusion: For localized Ewing sarcoma, chemotherapy administered every 2 weeks is more effective than chemotherapy administered every 3 weeks, with no increase in toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
The Statistical Analysis of Failure Time Data
Kalbfleisch, J. D., & Prentice, R. L. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781118032985 · Cited by 3,219
Clinical Trials: A Practical Approach.
Hill, I. D., & Pocock, S. J. (1984) · Biometrics · doi:10.2307/2531186 · Cited by 2,930
The Statistical Analysis of Failure Time Data
Klein, J. P. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,215
Discrete Multivariate Analysis
(1977) · Technometrics · doi:10.1080/00401706.1977.10489605 · Cited by 1,757
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Grier, H. E., Krailo, M. D., Tarbell, N. J., Link, M. P., Fryer, C. J. H., Pritchard, D. J., Gebhardt, M. C., Dickman, P. S., Perlman, E. J., Meyers, P. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020890 · Cited by 1,328
Self-citationThe Analysis of Failure Times in the Presence of Competing Risks
Prentice, R. L., Kalbfleisch, J. D., Peterson, A. V., Flournoy, N., Farewell, V. T., & Breslow, N. E. (1978) · Biometrics · doi:10.2307/2530374 · Cited by 1,266
Iacobuzio-Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C. M., Vilardell, F., Wang, Z., Keller, J. W., Banerjee, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7188 · Cited by 1,081
Nesbit, M. E., Gehan, E. A., Burgert, E. O., Vietti, T. J., Cangir, A., Tefft, M., Evans, R., Thomas, P., Askin, F. B., & Kissane, J. M. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.10.1664 · Cited by 570
Farrell, J. J., Elsaleh, H., Garcia, M., Lai, R., Ammar, A., Regine, W. F., Abrams, R., Benson, A. B., Macdonald, J., Cass, C. E., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.067 · Cited by 458
Burgert, E. O., Nesbit, M. E., Garnsey, L. A., Gehan, E. A., Herrmann, J., Vietti, T. J., Cangir, A., Tefft, M., Evans, R., & Thomas, P. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1514 · Cited by 380
Lewis, I. J., Nooij, M. A., Whelan, J., Sydes, M. R., Grimer, R., Hogendoorn, P. C. W., Memon, M. A., Weeden, S., Uscinska, B. M., van Glabbeke, M., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk015 · Cited by 346
Granowetter, L., Womer, R., Devidas, M., Krailo, M., Wang, C., Bernstein, M., Marina, N., Leavey, P., Gebhardt, M., Healey, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1478 · Cited by 330
Self-citationWoods, W., Kobrinsky, N., Buckley, J., Lee, J., Sanders, J., Neudorf, S., Gold, S., Barnard, D., DeSwarte, J., Dusenbery, K., et al. (1996) · Blood · doi:10.1182/blood.v87.12.4979.bloodjournal87124979 · Cited by 329
Crane, C. H., Varadhachary, G. R., Yordy, J. S., Staerkel, G. A., Javle, M. M., Safran, H., Haque, W., Hobbs, B. D., Krishnan, S., Fleming, J. B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8038 · Cited by 288
Picozzi, V. J., Kozarek, R. A., & Traverso, L. W. (2003) · The American Journal of Surgery · doi:10.1016/s0002-9610(03)00051-5 · Cited by 262
Smith, M. A., Ungerleider, R. S., Horowitz, M. E., & Simon, R. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.20.1460 · Cited by 202
Schmidt, J., Abel, U., Debus, J., Harig, S., Hoffmann, K., Herrmann, T., Bartsch, D., Klein, J., Mansmann, U., Jäger, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2960 · Cited by 167
Picozzi, V. J., Abrams, R. A., Decker, P. A., Traverso, W. L., O'Reilly, E. M., Greeno, E. W., Martin, R. C. G., Wilfong, L. S., Rothenberg, M. L., Posner, M. C., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq384 · Cited by 104
Womer, R. B., Daller, R., Fenton, J. G., & Miser, J. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00236-1 · Cited by 72
Self-citationParty, F. T. E. L. C. W., Jp, S., Paesmans, M., Lecomte, J., Cutsem, O. V., Lafitte, J., Berghmans, T., Koumakis, G., Florin, M., Thiriaux, J., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2114 · Cited by 67
Linehan, D. C., Tan, M. C. B., Strasberg, S. M., Drebin, J. A., Hawkins, W. G., Picus, J., Myerson, R. J., Malyapa, R. S., HULL, M. L., Trinkaus, K. M., et al. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318181e4e9 · Cited by 66
Morales‐Arias, J., Meyers, P. A., Bolontrade, M. F., et al. (2007) · Cancer · doi:10.1002/cncr.22964 · Cited by 36
Katz, M. H. G., Wolff, R. A., Crane, C. H., Varadhachary, G. R., Javle, M. M., Lin, E. H., Evans, D. B., Lee, J. E., Fleming, J. B., & Pisters, P. W. T. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1847-4 · Cited by 27
Borinstein, S. C., Pollard, J. A., Winter, L., & Hawkins, D. S. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22086 · Cited by 24
Saidi, R. F., ReMine, S. G., & Jacobs, M. J. (2007) · HPB · doi:10.1080/13651820701329241 · Cited by 19
The year of improved tissue acquisition, randomized trials, and endoscopic ultrasound-guided therapy
Bhutani, M. S. (2011) · Endoscopy · doi:10.1055/s-0031-1291444 · Cited by 13
Saidi, R. F., & Jacobs, M. J. H. M. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181a42218 · Cited by 10
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Smith, T. J., Bohlke, K., Lyman, G. H., Carson, K. R., Crawford, J., Cross, S. J., Goldberg, J. M., Khatcheressian, J. L., Leighl, N. B., Perkins, C. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3488 · Cited by 904
Grünewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0003-x · Cited by 873
Ewing Sarcoma: Current Management and Future Approaches Through Collaboration
Gaspar, N., Hawkins, D. S., Dirksen, U., Lewis, I. J., Ferrari, S., Le Deley, M.-C., Kovar, H., Grimer, R., Whelan, J., Claude, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5256 · Cited by 722
Self-citationCasali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy310 · Cited by 617
Metadata
- Authors
- Womer, R. B., West, D. C., Krailo, M. D., Dickman, P. S., Pawel, B. R., Grier, H. E., Marcus, K., Sailer, S., Healey, J. H., Dormans, J. P., & Weiss, A. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-11-20
- Volume
- 30
- Issue
- 33
- Pages
- 4148-4154
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2128628566
- Cited by
- 757
- References
- 32
- FWCI
- 27.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.